Service Overview

About the Immune Checkpoint Binding and Interaction Assays

Immune checkpoint proteins are surface molecules on immune effector cell populations that inhibit effector function when engaged to their cognate ligand(s). Expression of these ligands on cancer cells has been suggested as a mechanism by which these cells evade the immune response. Thus, therapeutics called immune checkpoint inhibitors that block interaction between the immune checkpoint protein and their ligands can restore the effector function of immune cells and promote tumor regression.

iQ’s Biosciences’ Immune Checkpoint Assays

iQ Biosciences is an immunology CRO with years of experience helping companies develop their immune checkpoint inhibitors, whether they are antibodies, peptides, or small molecules, using our immuno-oncology assays. We can help design a roadmap that begins with binding assays to screen for good candidates, proceeds to interaction assays with selected candidates for blocking ability, then progresses finally to functional assays that test for immuno-modulatory activity. See our Checkpoint Inhibitor Functional Assay for more information about functional assays. With this roadmap, we can demonstrate the binding, interaction, and functional properties of your molecules.

At the beginning of that roadmap, initial characterization of the checkpoint inhibitor is required to ensure its specificity for the immune checkpoint protein or its ligand, which can be accomplished using iQ Bioscience’s Immune Checkpoint Binding Assays. For these assays, we use a flow cytometry-based method to demonstrate binding of candidate molecules to cell lines expressing the protein of interest and to ensure specificity using cell lines that do not. Further evaluation of selected candidates can be tested for EC50 using this assay as having a selection of candidates with a wide range of EC50 is important. In some cases, candidates with the best EC50 are not necessarily the ones that move forward for development. See Figure 1 for an example of our Immune checkpoint Binding assay by flow cytometry.

Figure 1. EC50 binding curves of CD38 antibody binding to cell lines expressing different levels of CD38. Daudi, Raji, and Ramos cells were stained with increasing concentration of the same fluorescently-labeled CD38 antibody. Flow cytometric analysis was performed on the cells and the mean fluorescence intensity (MFI) was obtained. Graphpad Prism was used to generate the binding curve of antibody concentration versus MFI.

After initial characterization to establish specificity of your candidate checkpoint inhibitors, experiments must be performed to demonstrate it can block interaction between the checkpoint protein and its ligand. Without the ability to block engagement, the candidate is impractical as engagement will likely lead to lymphocyte inactivation. Indeed, the mechanism of action in current FDA approved checkpoint inhibitors is thought to be interference of binding between the immune checkpoint and its ligand. However, when screening antibodies that bind, there may be candidates that recognize the target, but do not prevent interaction with its ligand. Therefore, interaction assays must be performed to ensure the checkpoint inhibitor prevents engagement, which is an important factor to understand for a functional immune checkpoint inhibitor. See our Checkpoint Inhibitor Functional Assay for other factors to understand. At iQ Biosciences, we have developed custom Immune Checkpoint Interaction Assays using a flow cytometry-based method to screen for potential candidates that interfere with binding. In addition, these studies suggest a potential mechanism of action for the checkpoint inhibitor if immune response function is restored.

In conjunction with our immune checkpoint inhibitor functional assays, we can demonstrate the binding and interaction properties of your molecule(s) . iQ’s personalized service will work with you to design a roadmap to determine the best assays to fulfill your program’s scientific requirements and to ensure you receive the most relevant data. We are your immuno-oncology CRO to bring that roadmap into focus and to execute its studies. Please contact us for more information.

Request an Immune Checkpoint Assay Fact Sheet

Interested in learning more about our Immune Checkpoint Assay Bioservices? Complete the form below to request a Fact Sheet.

The iQ Experience

Tailored Experiments

Your research is important to us. Our scientists will work through each step of the process with you, including assay design, data analysis, and recommendations for future studies.

Streamlined Process

Simplify your workflow. Bypass the middle-man: at iQ Biosciences, you'll get immediate access to our biospecimen inventory, saving you both valuable time and money.

Expertise

We're experts- so you don't have to be. Augmenting years of experience in immunology and working with immune assays, our scientists stay current with the latest publications and technology.

Exceptional Service

We're here to help. We know the challenges you're facing: whether it be through expedited service or our complimentary consulting services, our team is dedicated to helping you reach your goals.

Order Information

Pricing

At iQ Biosciences, we understand that each client is unique. Upon quote request, we will provide complimentary consulting services to determine how to tailor our services to best meet your goals. Based on this preliminary assessment, we will be able to provide a price quote.

Expected Timetable

Fit a timetable appropriate to your research goals. We work with you to determine your expected turn-around on a case-by-case basis and ensure that our services fit your needs. Some experiments may require an expedited service – please inquire for more information.

Contact Us

Questions? We’d love to hear from you. Give us a call or leave a message below and we’ll be in contact. Thanks!